Northwest Biotherapeutics, Inc. Stock Börse Stuttgart
Stocks
NBYB
US66737P6007
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Börse Stuttgart
07:31:31 29/09/26 pm AEST
|
5-day change | 1st Jan Change | ||
| 0.1250 EUR | -4.58% |
|
-21.88% | -39.32% |
| Market Cap | 260M 229M 216M 196M 368M 24.97B 371M 2.59B 1B 12.74B 977M 955M 40.94B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 356M 313M 296M 269M 505M 34.19B 508M 3.55B 1.37B 17.45B 1.34B 1.31B 56.07B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 9.89x |
| Free-Float |
95.22% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -4.58% | ||
| 1 week | -21.88% | ||
| Current month | -13.19% | ||
| 1 month | -13.19% | ||
| 3 months | -24.70% | ||
| 6 months | -26.47% | ||
| Current year | -39.32% |
| 1 week | 0.12 |  | 0.18 |
| 1 month | 0.12 | | 0.19 |
| Current year | 0.1 | | 0.38 |
| 1 year | 0.1 | | 0.38 |
| 3 years | 0.1 | | 0.93 |
| 5 years | 0.1 | | 2.18 |
| 10 years | 0.1 | | 2.18 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alton Boynton
CEO | Chief Executive Officer | 82 | 01/06/2007 |
Linda Powers
CEO | Chief Executive Officer | 71 | 08/06/2011 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/01/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Alton Boynton
BRD | Director/Board Member | 82 | 01/01/1998 |
Linda Powers
CHM | Chairman | 71 | 17/05/2007 |
Navid Malik
BRD | Director/Board Member | 57 | 01/04/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.58% | -21.88% | - | - | 260M | |
| -0.37% | -3.67% | +57.21% | +87.75% | 71.81B | |
| +0.88% | -0.37% | +39.43% | +85.02% | 60.06B | |
| +0.19% | +1.61% | +35.10% | +17.20% | 27.93B | |
| -0.14% | -2.75% | -14.13% | +356.79% | 25.7B | |
| +0.57% | +1.10% | +1.02% | -2.89% | 24.89B | |
| +0.59% | +1.32% | +26.04% | -7.93% | 20.92B | |
| -1.70% | +0.43% | +150.24% | +323.16% | 15.04B | |
| +0.36% | +2.01% | +49.51% | +160.70% | 14.46B | |
| +3.91% | -3.51% | -4.56% | +517.49% | 13.87B | |
| Average | -0.03% | -1.52% | +37.76% | +170.81% | 30.52B | |
| Weighted average by Cap. | +0.32% | -1.91% | +38.51% | +128.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 38.93M 34.24M 32.38M 29.37M 55.16M 3.74B 55.48M 388M 150M 1.91B 146M 143M 6.13B |
| Net income | - | - |
| Net Debt | 96.08M 84.5M 79.91M 72.48M 136M 9.22B 137M 957M 370M 4.71B 361M 353M 15.12B | 125M 110M 104M 94.24M 177M 11.99B 178M 1.24B 480M 6.12B 469M 459M 19.67B |
Employees
105
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/09/26 | EUR 0.1250 | -4.58% | 0 |
| 28/09/26 | EUR 0.1310 | -3.68% | 10,000 |
| 25/09/26 | EUR 0.1360 | +11.48% | 26,362 |
| 24/09/26 | EUR 0.1220 | -14.08% | 18,438 |
| 23/09/26 | EUR 0.1420 | -11.25% | 10,500 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1525USD
Average target price
1.000USD
Spread / Average Target
+555.74%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- NWBO Stock
- NBYB Stock
Select your edition
All financial news and data tailored to specific country editions
